Sign up for periodic reports and bulletins
FREE access; FREE of commercials; FREE to use
Posted July 14, 2013: by Bill Sardi
Various skeptics challenged my online report of a study published in the journal Anticancer Research that 345 patients with end-stage spreading (metastatic) cancer at a clinic in Japan had been successfully treated with immunotherapy. That published report presented three cases as examples. Skeptics claimed only 3 of the 345 treated patients were successfully treated.
I have received confirmation directly from the Saisei Mirai Clinic in Kobe, Japan, that these patients were successfully treated and are in 1-2 year remission following treatment with injectable Gc-MAF (macrophage activating factor), intravenous vitamin C and oral vitamin D plus lipoic acid. The clinic doctors report few if any side effects, improved quality of life, increased appetite in end-stage patients and prolonged survival. The e-mail received from Japan can be read below.
From: Saisei Mirai Clinic
Subject: Re: Inquiry: GcMAF
Date: July 13, 2013 1:35:59 AM PDT
To: Bill Sardi
Thank you for your email. I’m sorry about the late reply. I got your email from Dr Sakamoto. He asked me to reply to you. My name is Martin Mette. I’m working with the other researchers and doctors on second generation GcMAF. I’ll try to answer your questions.
There are generally no significant side effects with second generation GcMAF therapy except occasionally mild swelling, mild pain, itching, and slight redness at the injection site which is seen occasionally in a similar way to other injections. Low grade fever or eczema has been observed in about 1 out of 100 patients using GcMAF, but these were short-term effects. We have used high doses of GcMAF for critically ill patients without any problems at all. In fact we see improved quality of life, increased survival and increase appetite in advanced stage patients.
Patients are treated naturally in a clinical setting. There are no drop outs unless the patient cannot continue due to reasons other than GcMAF therapy. It’s important to bear in mind that most patients come to our clinic only after they have exhausted most conventional options for treatment and the cancer is progressing or recurring. So these are the most challenging to cure.
We don’t treat many non-solid tumors such as leukemia, but we are planning to treat these more in the near future. We have treated patients with lymphoma.
We’d be happy to lecture on our experience with GcMAF, but currently we haven’t made any plans for lectures outside Japan.
We are seeing increased interest from doctors in Japan and more doctors are starting to allow patients to seek additional treatment with GcMAF at our clinic.
Please let me know if you have any questions.
You must be logged in to post a comment.